

Genomic health test could reduce overtreatment of breast cancer

from Forbes

Recently, the San Antonio Breast Cancer Symposium featured new evidence for a tool that might inform treatment decisions in women with low-grade breast tumors. Since the 1980s, diagnoses of DCIS (ductal carcinoma in situ) have risen dramatically due to enhanced screening. Questions about this condition — whether it's likely to cause harm and how to manage it — are central to debate about mammography, the concept of overdiagnosis, and overtreatment. [more](#)